Skip to main content

REVIEW article

Front. Immunol.
Sec. Inflammation
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1495206
This article is part of the Research Topic Molecular Mechanisms and Therapeutic Strategies in Inflammation View all articles

Aquaporins in sepsis-an update

Provisionally accepted
Katharina Rump Katharina Rump 1,2*Michael Adamzik Michael Adamzik 2
  • 1 Ruhr University Bochum, Bochum, Germany
  • 2 Klinik für Anästhesiologie und Intensivmedizin am Universitätsklinikum Knappschaftskrankenhaus Bochum., Bochum, Germany

The final, formatted version of the article will be published soon.

    Aquaporins (AQPs), membrane proteins that transport water and small solutes, are increasingly recognized for their role in sepsis, particularly in immune modulation, metabolism, and organ protection. Sepsis, marked by an excessive immune response to infection, leads to organ failure and high mortality. Recent research highlights AQPs, especially aquaglyceroporins like AQP3, AQP7, AQP9, and AQP10, as key players in immune cell metabolism, offering new therapeutic possibilities. In sepsis, immune cells shift from oxidative phosphorylation to aerobic glycolysis for faster ATP production, a process aided by AQPs. AQP3, for example, transports glycerol to fuel glycolysis and regulate glucose uptake, while AQP7 influences lipid metabolism and promotes energy production via p38 signaling. Beyond metabolism, AQPs are crucial for immune functions: AQP9 aids neutrophil migration and activation, critical for infection control, while AQP3 modulates inflammation through the TLR4 pathway. AQP1 helps protect against lipopolysaccharide (LPS)-induced kidney injury by promoting macrophage polarization via the PI3K pathway. Therapeutically, AQPs show promise in reducing sepsis-induced organ damage. Inhibiting AQP9 with compounds like HTS13286 or RG100204 decreases inflammation and improves survival by modulating NF-κB signaling. Methazolamide and furosemide, which target AQP5, have reduced lung injury in animal models, showing potential for treating acute lung injury (ALI). Additionally, regulating AQP1 through non-coding RNAs could offer new strategies to mitigate inflammatory responses and organ damage. AQPs also emerge as potential biomarkers for sepsis progression. Altered AQP expression, such as AQP1, AQP3, and AQP5, correlates with sepsis severity, while AQP5 polymorphisms are linked to better outcomes in sepsis-related acute respiratory distress syndrome (ARDS). This suggests AQPs could be used to personalize treatments based on individual profiles. In conclusion, AQPs play a critical role in sepsis, from immune metabolism to inflammation. Targeting AQPs presents novel therapeutic opportunities to improve outcomes and reduce organ damage in sepsis patients.

    Keywords: aquaporin (AQP), AQP9 aquaporin-9, drug target, Sepsis, pathophysiology sepsis, AQP5 aquaporin 5, AQP3, Immune metabolism

    Received: 12 Sep 2024; Accepted: 14 Oct 2024.

    Copyright: © 2024 Rump and Adamzik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Katharina Rump, Ruhr University Bochum, Bochum, Germany

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.